Stem Cell Therapy Safety and Guarantees FAQs in India

Generally yes, when performed at accredited centers that follow ICMR guidelines. Not every provider follows approved protocols, so verifying the clinic matters.

No. Only therapies approved for specific indications are regulated by CDSCO and ICMR. Many experimental offerings remain unproven and are not officially authorized.

Risks include infection, immune rejection, tumor formation, and poor treatment outcomes. Always verify a clinic's credentials and licensing before proceeding.

The risk is extremely low when proper protocols are followed, but poorly handled cells at unregulated clinics can carry a small risk of abnormal cell growth.

Yes, when properly screened and matched. Strict donor testing and processing minimize the risk of rejection or infection.

The Indian Council of Medical Research (ICMR) and the Central Drugs Standard Control Organization (CDSCO) oversee ethical and scientific practice in stem cell use.

Yes. Clinics must follow ICMR guidelines and register with CDSCO for clinical use, particularly when working with minimally manipulated cells or investigational treatments.

Yes. You must be informed about the procedure, benefits, risks, and alternatives before treatment begins.

Look for government registration, published research, medical licenses, patient reviews, and transparency around procedure and pricing.

Yes. Embryonic stem cell use is highly restricted in India and requires specific ethical approvals.

No responsible clinic guarantees outcomes, since stem cell therapy is still an evolving field. Promises of a guaranteed cure are a red flag.

Success rates vary by condition, patient health, and technique used. Some orthopedic and neurological applications show encouraging results, but rates are not uniform.

Results can take weeks to months, and some patients need multiple sessions or adjunct therapies.

In many cases it may slow progression or ease symptoms, but it is not a guaranteed cure.

Responsible clinics offer follow-up and alternative care plans. Refunds are uncommon, though some clinics provide adjustments or additional sessions.

Sources include bone marrow, adipose tissue, umbilical cord blood, and dental pulp. Cells may be autologous (from the patient) or allogeneic (from a donor).

Yes, when sourced from licensed cord blood banks that follow strict screening and handling protocols.

Often yes, since it reduces the risk of an immune reaction, though effectiveness still depends on your overall health condition.

Cells should be processed in GMP-certified labs under sterile, quality-controlled conditions. Ask your clinic about its lab standards directly.

Contamination is a real risk, which is why GMP protocols matter; the risk is very low at properly certified centers.

Yes, but only for approved conditions and under clinical trial or therapeutic use as regulated by CDSCO and ICMR.

Yes. Legal action is possible under India's consumer protection and medical negligence laws, especially where there is malpractice or false claims.

Hematopoietic stem cell transplant is approved for blood disorders. Most other applications remain investigational.

Yes. A qualified physician must assess your eligibility before treatment begins.

India offers comparatively affordable treatment versus Western countries, though prices vary; expect roughly $8,000 to $12,000 depending on the condition and number of sessions.

Most Indian insurers do not cover stem cell therapy unless it is part of an approved bone marrow transplant.

Yes. Many reputed institutions offer clinical trials — check with ICMR or hospitals such as AIIMS, PGIMER, or private research facilities.

Yes. Depending on the condition, options may include physiotherapy, PRP therapy, surgery, or conventional medication — discuss all alternatives with a specialist.